AIM | tickerfilter.com

Fundamental analysis

32%

Profitability 35%

Dept financing 43%

Liquidity 14%

Performance 30%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-22.87%

1 Month

-33.65%

3 Months

-52.38%

6 Months

-71.31%

1 Year

467.26%

2 Year

415.46%

Key data

Stock price

$0.70

P/E Ratio

0.00

DAY RANGE

$0.67 - $0.78

EPS

-$2.21

52 WEEK RANGE

$0.06 - $20.35

52 WEEK CHANGE

$432.32

MARKET CAP

7.422 M

YIELD

N/A

SHARES OUTSTANDING

2.853 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-15-2025

BETA

0.00

PUBLIC FLOAT

N/A

AVERAGE 10 VOLUME

$291,953

AVERAGE 30 VOLUME

$3,793,536

Company detail

CEO: Thomas K. Equels
Region: US
Website: aimimmuno.com
Employees: 20
IPO year: 2013

Issue type:
Market: NYSE American
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

AIM ImmunoTech Inc. focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS) It is also developing Ampligen for the. treatment of renal cell carcinoma, malignant melanoma,. non-small cell lung, ovarian, breast,. breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis

AIM - AIM ImmunoTech Inc.